Rituximab in patients with mucosal-associated lymphold tissue-type lymphoma of the ocular adnexa

Eight patients with ocular adnexal mucosal-associated lymphpid tissue (MALT) lymphoma. were treated with rituximab, at diagnosis (n=5) or relapse (n=3). All untreated patients achieved lymphoma regression, while relapsing patients had no benefit. Four responding patients experienced early relapse. The median time to progression was 5 months. The efficacy of rituximab in ocular adnexal lymphoma is lower than that reported for gastric MALT lymphomas.